A Phase I Study of DFP-13318 in Patients With Advanced Solid Tumors

Trial Profile

A Phase I Study of DFP-13318 in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs PL 0264 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Delta-Fly Pharma
  • Most Recent Events

    • 18 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 02 Jun 2015 According to ProLynx media release, Investigational New Drug (IND) application for PL 0264 (PEG-SN-38) filed with US FDA is active and this trial is expected to initiate in 2015.
    • 07 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top